Clinical Trials Logo

Clinical Trial Summary

This study is locally amended study from CSTI571K2301 to evaluate the efficacy and safety of high-dose Glivec in Korean patients group with chronic phase of CML. Molecular response at 60 months after Glivec administration will be described.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01216085
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date August 2010
Completion date July 2011

See also
  Status Clinical Trial Phase
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Terminated NCT01131325 - Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations Phase 4
Active, not recruiting NCT03578367 - Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Phase 2
Completed NCT03747679 - Palatability (Taste) of Oral Formulations of Bosutinib Phase 1
Completed NCT01019317 - Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Phase 2
Recruiting NCT06131801 - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Not yet recruiting NCT06423911 - A Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With CML Phase 3
Completed NCT03880617 - Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy
Completed NCT00858572 - STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders Phase 1
Completed NCT00684008 - Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant Phase 1
Completed NCT00013533 - Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies Early Phase 1
Not yet recruiting NCT06047886 - CD34 Selection Using the Automated CliniMACS Prodigy Phase 1
Recruiting NCT05823571 - Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Phase 1
Completed NCT00780104 - Sirolimus in Combination With MEC in High Risk Myeloid Leukemias Phase 1
Recruiting NCT06211166 - Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
Recruiting NCT01762969 - Treatment Modification Based on Early Assessment of CML Patients Phase 2
Completed NCT00891592 - Umbilical Cord Blood Transplant for Hematological Malignancies Phase 1
Terminated NCT00776373 - Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00511537 - Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders N/A
Recruiting NCT05152537 - FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor(TKI)Stopping in Chronic Myeloid Leukemia